Edition:
United Kingdom

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.41USD
16 Jan 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.41
Open
$1.46
Day's High
$1.47
Day's Low
$1.40
Volume
78,464
Avg. Vol
119,111
52-wk High
$3.08
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Healios To Make Payment To Extend Exclusive Period For Negotiating Option For License To Multistem Therapy For Indications In China
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Athersys Inc ::HEALIOS AGREES TO MAKE PAYMENT TO EXTEND EXCLUSIVE PERIOD FOR NEGOTIATING AN OPTION FOR A LICENSE TO MULTISTEM® THERAPY FOR INDICATIONS IN CHINA.ATHERSYS INC - HEALIOS HAS AGREED TO MAKE A ONE-TIME $2.0 MILLION PAYMENT IN DECEMBER 2018 FOR AN EXTENSION THROUGH JUNE 30, 2019.ATHERSYS INC - HEALIOS MAY MAKE ADDITIONAL PAYMENT OF $3.0 MILLION TO EXTEND NEGOTIATION PERIOD THROUGH DEC31, 2019.ATHERSYS - PAYMENTS BY HEALIOS WOULD BE CREDITABLE AGAINST $15 MILLION OPTION FEE THAT WOULD BE PAYABLE UPON EXECUTION OF CHINA OPTION AGREEMENT.  Full Article

Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements
Tuesday, 1 May 2018 

May 1 (Reuters) - Healios KK <4593.T>::ATHERSYS AND HEALIOS EXTEND BY ONE MONTH THE PERIOD TO COMPLETE COLLABORATION EXPANSION AGREEMENTS.ATHERSYS INC - CO, HEALIOS K.K. AGREED TO EXTEND PERIOD FROM APRIL 30, 2018 TO MAY 31, 2018.  Full Article

Athersys reports Q3 loss per share $0.06
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article